Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Moleculin Biotech, Inc.
REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018
11 déc. 2018 07h30 HE
|
Moleculin Biotech, Inc.
HOUSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces Conference Call to Discuss FDA Filing and New Immune Checkpoint Data on Wednesday, December 12, 2018
06 déc. 2018 16h05 HE
|
Moleculin Biotech, Inc.
HOUSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces FDA Filing for Orphan Drug Designation for Glioblastoma Drug
06 déc. 2018 07h30 HE
|
Moleculin Biotech, Inc.
HOUSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces Breakthrough Discovery for its WP1066
04 déc. 2018 07h30 HE
|
Moleculin Biotech, Inc.
WP1066 shown to counteract resistance to checkpoint blockades HOUSTON, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
Moleculin Announces New Data Further Supporting Its Lead Drug for Treating Pancreatic Cancer
28 nov. 2018 07h30 HE
|
Moleculin Biotech, Inc.
WP1732 shown to accumulate beneficially in pancreas HOUSTON, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
Moleculin Requests FDA Meeting Regarding IND for New Cancer Drug
15 nov. 2018 07h30 HE
|
Moleculin Biotech, Inc.
Testing confirms ability of WP1732 to target pancreatic cancer HOUSTON, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2018
13 nov. 2018 07h30 HE
|
Moleculin Biotech, Inc.
HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122
08 nov. 2018 07h30 HE
|
Moleculin Biotech, Inc.
Documented potential for drug candidate with characteristics like WP1122 to reverse immune suppression HOUSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX)...
Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial
01 nov. 2018 07h30 HE
|
Moleculin Biotech, Inc.
WP1066 demonstrating drug bioavailability in on-going Phase 1 clinical trial HOUSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a...
Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials
25 oct. 2018 07h30 HE
|
Moleculin Biotech, Inc.
HOUSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...